Patients in the STAMPEDE trial, on the other hand, had more advanced T2D, with an average disease duration of more than eight years and a mean baseline glycated hemoglobin level of 8.9% to 9.5%, while being treated with about three diabetes medications, including insulin. Here, INS is linked to type 2 diabetes mellitus.